治療方案 ​

Lipitor®膽固清®

阿托伐他汀 – 全港最多受訪醫生選用的膽固醇藥2

Lipitor®膽固清®（通用名稱：阿托伐他汀鈣［結晶型］atorvastatin calcium［crystalline form］）是一種能降低膽固醇的他汀類藥物 1

為何選擇Lipitor®膽固清®

膽固清®經多過400個臨床研究驗証，超過25年的臨床經驗，至今累積幫助的病人年超過3億。3

國際指南建議

Atorvastatin 目前為英國國家臨床卓越研究院NICE（National Institute for Health and Care Excellence）、美國心臟協會AHA（American Heart Association）及歐洲心臟病學會ESC（European Society of Cardiology）多份國際指引的一線藥物之一。4-6​

  • 參考資料PM-COR-24-102902 NOV 2024

    1. Lipitor® (atorvastatin) Prescribing Information: Version April 2024
    2. Ipsos Healthcare 2020 Lipid Lowering Agent Preference Study Interviewed 200 HCPs (Cardiologists, Endocrinologists, Nephrologists, Neurologists and GP/IM/GOPC) in Hong Kong March – May 2020.
    3. Data on file. Viatris.
    4. Cardiovascular disease: risk assessment and reduction, including lipid modification. Clinical guideline [NG238]. National Institute for Health and Care Excellence. 2024. Available at: https://www.nice.org.uk/guidance/ng238. Accessed on September 14, 2024.
    5. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/ NLA/PCNA Guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285-e350.
    6. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188.

相關疾病

心血管疾病

了解更多...